(Q38147336)

29 August 2017

title

The discovery and development of boceprevir (English)

1 reference

29 August 2017

David P Rotella

1

1 reference

29 August 2017

language of work or name

English

0 references

publication date

30 September 2013

1 reference

Expert Opinion on Drug Discovery

29 August 2017

published in

1 reference

29 August 2017

volume

8

1 reference

29 August 2017

issue

11

1 reference

29 August 2017

page(s)

1439-1447

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

HCV genotyping using statistical classification approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Molecular targets for flavivirus drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Solution structure and dynamics of the single-chain hepatitis C virus NS3 protease NS4A cofactor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Combined X-ray, NMR, and Kinetic Analyses Reveal Uncommon Binding Characteristics of the Hepatitis C Virus NS3-NS4A Protease Inhibitor BI 201335

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

A continuous spectrophotometric assay for the hepatitis C virus serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Hepatitis C virus NS3-4A serine protease inhibitors: SAR of P'2 moiety with improved potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Proline-based macrocyclic inhibitors of the hepatitis C virus: stereoselective synthesis and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.843525

10.1517/17460441.2013.843525

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference